Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis
Trial details
- Registry ID
- NCT04365868
- Drugs studied
- belapectin
TrialRedline tracks 1 clinical trial sponsored by Galectin Therapeutics Inc.: 1 Phase 2 / 3.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH CirrhosisNCT04365868 | belapectin | Terminated | 2025-03-11Actual |
Names as written in the registry records.
NCT04365868 · Galectin Therapeutics Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Proportion of patients in the belapectin treatment groups who develop new esophageal varices at 78 weeks [18 months] of treatment compared to placebo. After: Measure: Proportion of Patients in the Belapectin Treatment Groups Who Develop New Esophageal Varices at 78 Weeks [18 Months] of Treatment Compared to Placebo.
NCT04365868 · Galectin Therapeutics Inc.
Before: Active not recruiting. After: Terminated.